IPIFINI President Appointed to ProNai's Scientific Advisory Board

PRONAI ANNOUNCES NEW SCIENTIFIC ADVISORY BOARD
Pioneer in DNAi®-based drug development brings aboard top experts in genomics, oncology, oligonucleotides, preclinical and clinical development...
Kalamazoo, Michigan – October 12, 2006 – ProNAi Therapeutics, Inc., a biopharmaceutical company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi®), today announced that it has named its new Scientific Advisory Board team, composed of distinguished researchers and professionals in genomics, oligonucleotides, preclinical and clinical drug development.

Dr. Richard D. Gill, President and CEO of ProNAi, said, “ProNAi is delighted to have such a remarkable and highly experienced Scientific Advisory Board team working closely with us as we bring our PNT100 cancer therapeutic candidate into the clinic. With such a vast range of distinguished expertise in both our core scientific and business segments, our SAB members represent the top-tier of research, drug development and market expertise that ProNAi has brought to bear in support of developing a new class of DNAi®-based drugs.”

Robert Forgey, Chief Operating Officer of ProNAi, said, “The prominence of each of our Scientific Advisory Board members in their respective fields speaks for itself. Each is a noted and respected leader in genomics, oncology, oligonucleotides, preclinical and clinical drug development, hailing from prestigious institutions. We look forward to creating compelling and fascinating scientific research and results together.” ProNAi’s new Scientific Advisory Board team comprises:

• Tod Woolf, Ph.D. Founder and CEO, IPIFINI, Inc. Sudbury, MA; Founder Sequitur, sold to Invitrogen
• Cy Stein, MD, PhD, Professor and Head Genitourological Cancer, Albert Einstein College of Medicine, New York, NY
• Mace Rothenberg, MD, Ingram Professor of Cancer Research and Professor of Medicine, Vanderbilt Medical School, Nashville, TN
• Ayad Al-Katib, MD, Head Oncology, St. Johns Medical Center, Detroit, MI; Professor of Medicine, Wayne State University Medical School, Detroit, MI
• David Olson, PhD, Vice President Research PanCell, Co-founder Gentera, Ann Arbor, MI; Chief Business Development Officer, Accuri Instruments, Inc., Ann Arbor, MI; Co-Founder, President and Chief Executive Officer, The Fund for Autoimmune Research, Ann Arbor, MI
• Craig Webb, PhD, Director and Principal Investigator, Tumor Metastasis and Angiogenesis Laboratory; Director, Multiple Myeloma Laboratory, Van Andel Research Institute, Grand Rapids, MI
• John Schimenti, PhD, Professor and Director, Vertebrate Genomics, Cornell University, Ithaca, NY
• Terry Magnuson, PhD, Professor and Chair Genetics, University of North Carolina, Chapel Hill, NC

About ProNAi Therapeutics, Inc.

ProNAi Therapeutics, Inc. is a biopharmaceutical drug development company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi®), which employs single strands of DNA to target and treat non-transcribed regions of genomes responsible for complex genetic diseases. ProNAi is currently developing multiple DNAi®-based drug candidates with the potential to treat multiple cancers, including non-Hodgkin's lymphoma, prostate, breast, and colon cancers. The company’s lead drug candidate, PNT100, which has demonstrated in vivo efficacy in a variety of human tumor xenograft models, is currently in preclinical development. ProNAi is also exploring the potential of DNAi®-based therapies for indications such as diabetes, Alzheimer's and inflammatory disease.

ProNAi is based in Kalamazoo, Michigan. For more information, please visit: www.pronai.com.

more...